COVID-19 mRNA vaccine / CanSino - LARVOL DELTA

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P1 | N=43 | Completed | Sponsor: CanSino Biologics Inc. | Active, not recruiting ➔ Completed | N=150 ➔ 43

Enrollment change • Trial completion • Infectious Disease • Novel Coronavirus Disease

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P2 | N=150 | Completed | Sponsor: CanSino Biologics Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults. (PubMed, J Infect) - P1 | "At day 28 after the full vaccination, both the low-dose and the high-dose CS-2034 vaccine were able to induce the production of high titers of S-RBD IgG antibodies against the BA.1 strain. Adverse reactions in the low-dose and high-dose groups were mainly of severity grade 1 or 2, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine."

Clinical • Journal • P1 data • Dermatology • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Pruritus • Respiratory Diseases • CD4 • IFNG • IL2 • IL4 • TNFA

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Trial primary completion date: Jul 2023 ➔ Dec 2023

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • IL17A

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P1 | N=150 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | N=43 ➔ 150 | Trial completion date: Sep 2023 ➔ Dec 2023 | Trial primary completion date: Aug 2023 ➔ Nov 2023

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P1 | N=43 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting | N=80 ➔ 43 | Trial primary completion date: May 2023 ➔ Aug 2023

Enrollment change • Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P2 | N=150 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting | N=300 ➔ 150

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • IL17A

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • IL17A

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern. (PubMed, Emerg Microbes Infect) - "The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high level cross-reactive neutralization for Beta, original, Delta and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P2 trial • Infectious Disease • Novel Coronavirus Disease • IFNG • IL17A

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P1 trial • Infectious Disease • Novel Coronavirus Disease